Research Article

A Modified Recombinant DNA-Based SARS-CoV-2 Vaccine Expressing Stabilized Uncleavable Spike Protein Elicits Humoral and Cellular Immunity against Various SARS-CoV-2 Variants of Concern

Figure 2

Humoral response in VIU-1007 immunized mice. (a) Representation of mice immunization plan. Mice were grouped into four sets (seven mice/set) and immunized intramuscularly with either two or three doses of VIU-1007 or control plasmid (100 µg/mouse) every 21 days. Blood samples were withdrawn from immunized mice 3 weeks post-second (Day 42) or -third dose (Day 63) to assess humoral responses. (b) Mean endpoint titers of SARS-CoV-2 S1 specific binding total IgG, IgG1, and IgG2 as measured by ELISA after two and three doses are shown. IgG2 : IgG1 ratios are determined from samples collected after two or three doses of VIU-1007 or control plasmid. Data are shown as mean ± SD. Statistical significance is described as , , and .
(a)
(b)